High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.

Autor: Kruger DT; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam/Cancer Center Amsterdam, The Netherlands., Jansen MPHM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Konings IRHM; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam/Cancer Center Amsterdam, The Netherlands., Dercksen WM; Department of Medical Oncology, Maxima Medical Centre, Eindhoven, The Netherlands., Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Oulad Hadj J; Department of Medical Oncology, Gelre Ziekenhuis, Apeldoorn, The Netherlands., Sleijfer S; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Martens JWM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Boven E; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam/Cancer Center Amsterdam, The Netherlands.

Publikováno v: Molecular oncology [Mol Oncol] 2020 Mar; Vol. 14 (3), pp. 490-503. Date of Electronic Publication: 2020 Feb 07.